These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20953801)

  • 1. Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study.
    Timilshina N; Hussain S; Breunis H; Alibhai SM
    Support Care Cancer; 2011 Nov; 19(11):1815-21. PubMed ID: 20953801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai S
    Cancer; 2012 Apr; 118(7):1940-5. PubMed ID: 22009684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
    Beer TM; Tangen CM; Bland LB; Hussain M; Goldman BH; DeLoughery TG; Crawford ED;
    Cancer; 2006 Aug; 107(3):489-96. PubMed ID: 16804926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.
    Alibhai SM; Timilshina N; Duff-Canning S; Breunis H; Tannock IF; Naglie G; Fleshner NE; Krahn MD; Warde P; Marzouk S; Tomlinson GA
    Cancer; 2017 Jan; 123(2):237-244. PubMed ID: 27583806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
    Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
    Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
    Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
    BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
    Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
    Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
    World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact of androgen-deprivation therapy on physical function and quality of life.
    Alibhai SM; Breunis H; Timilshina N; Naglie G; Tannock I; Krahn M; Warde P; Fleshner NE; Canning SD; Tomlinson G
    Cancer; 2015 Jul; 121(14):2350-7. PubMed ID: 25809861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai SM
    J Urol; 2012 Dec; 188(6):2183-8. PubMed ID: 23083859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
    Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer.
    Keating MJ; Giscombe L; Tannous T; Reddy N; Mukkamalla SKR; DeSouza A; Rathore R
    J Oncol Pharm Pract; 2019 Dec; 25(8):1927-1932. PubMed ID: 30880568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
    Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
    BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.